[1] [1] LEE Y, CHOE J, PARK O H, et al. Molecular mechanisms driving mRNA degradation by m6A modification[J]. Trends Genet, 2020, 36(3): 177-188.

[2] [2] ZHANG L, WANG X, ZHAO W, et al. Overview of m6A and circRNAs in human cancers[J]. J Cancer Res Clin Oncol, 2023, 149(9): 6769-6784.

[3] [3] GE R, YE C, PENG Y, et al. m6A-SAC-seq for quantitative whole transcriptome m6A profiling[J]. Nat Protoc, 2023, 18(2): 626-657.

[4] [4] LAN Q, LIU P Y, HAASE J, et al. The critical role of RNA m6A methylation in cancer[J]. Cancer Res, 2019, 79(7): 1285-1292.

[5] [5] YIN H, ZHANG X, YANG P, et al. RNA m6A methylation orchestrates cancer growth and metastasisviamacrophage reprogramming[J]. Nat Commun, 2021, 12(1): 1394.

[6] [6] LI C, GUI G, ZHANG L, et al. Overview of methionine adenosyltransferase 2A (MAT2A) as an anticancer target: structure, function, and inhibitors[J]. J Med Chem, 2022, 65(14): 9531-9547.

[7] [7] HUANG Q, MO J, LIAO Z, et al. The RNA m6A writer WTAP in diseases: structure, roles, and mechanisms[J]. Cell Death Dis, 2022, 13(10): 852.

[8] [8] LIN X, WANG F, CHEN J, et al. N6-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance[J]. Mil Med Res, 2022, 9(1): 19.

[10] [10] AZZAM S K, ALSAFAR H, SAJINI A A. FTO m6A demethylase in obesity and cancer: implications and underlying molecular mechanisms[J]. Int J Mol Sci, 2022, 23(7): 3800.

[11] [11] QU J, YAN H, HOU Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol, 2022, 15(1): 8.

[12] [12] DU C, LV C, FENG Y, et al. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3Baxisfacilitatesprostate cancer progression[J]. J Exp Clin Cancer Res, 2020, 39(1): 223.

[13] [13] CHENG Y, XIE W, PICKERING B F, et al. N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation[J]. Cancer Cell, 2021, 39(7): 958-972. e8.

[14] [14] HONG J, XU K, LEE J H. Biological roles of the RNA m6A modification and its implications in cancer[J]. Exp Mol Med, 2022, 54(11): 1822-1832.

[15] [15] HE P C, HE C. m6A RNA methylation: from mechanisms to therapeutic potential[J]. EMBO J, 2021, 40(3): e105977.

[16] [16] LIU T, YANG S, SUI J, et al. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer[J]. J Cell Physiol, 2020, 235(1): 548-562.

[17] [17] LU J, RU J, CHEN Y, et al. N6-methyladenosine-modified circSTX6 promotes hepatocellular carcinoma progression by regulating the HNRNPD/ATF3 axis and encoding a 144 amino acid polypeptide[J]. ClinTranslMed, 2023, 13(10): e1451.

[18] [18] OU X, TAN Y, XIE J, et al. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer[J]. Drug Resist Updat, 2024, 73: 101063.

[19] [19] CHEN F, CHEN Z, GUAN T, et al. N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis[J]. Cancer Res, 2021, 81(11): 2847-2860.

[20] [20] XU X, QIU S, ZENG B, et al. N6-methyladenosine demethyl-transferase FTO mediated m6A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis[J]. Oncogene, 2024, 43(17): 1288-1302.

[21] [21] CHANG G, SHI L, YE Y, et al. YTHDF3 induces the translation of m6A-enriched gene transcripts to promote breast cancer brain metastasis[J]. Cancer Cell, 2020, 38(6): 857-871. e7.

[22] [22] SINGH S, GUPTA S, ABHISHEK R, et al. Regulation of m6A (N6-Methyladenosine) methylation modifiers in solid cancers[J]. Funct Integr Genomics, 2024, 24(6): 193.

[23] [23] SHAN M, LIU D, SUN L, et al. KIAA1429 facilitates metastasisviam6A-YTHDC1-dependent RND3 down-regulation in hepatocellular carcinoma cells[J]. Cancer Lett, 2024, 584: 216598.

[24] [24] WANG Y, YANG Y, YANG Y, et al. Hypoxia induces hepatocellular carcinoma metastasisviathe HIF-1/METTL16/lnc-CSMD1-7/RBFOX2 axis[J]. iScience, 2023, 26(12): 108495.

[25] [25] WANG Y, WANG Y, PATEL H, et al. Epigenetic modification of m6A regulator proteins in cancer[J]. Mol Cancer, 2023, 22(1): 102.

[26] [26] ZHAO B, HUANG C, PAN J, et al. circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p[J]. Cell Death Dis, 2022, 13(12): 1030.

[28] [28] WANG T, LI W, YE B, et al. FTO-stabilized lncRNA HOXC13-AS epigenetically upregulated FZD6 and activated Wnt/-catenin signaling to drive cervical cancer proliferation, invasion, and EMT[J]. J BUON, 2021, 26(4): 1279-1291.

[29] [29] QIU J, ZHAO R, MA C, et al. O-GlcNAcylation stabilized WTAP promotes GBM malignant progression in an N6-methyladenosine-dependent manner[J]. Neuro Oncol, 2024: no-ae268.

[30] [30] JIN S, LI M, CHANG H, et al. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKK/TBK1/IRF3 pathway in head and neck squamous cell carcinoma[J]. Mol Cancer, 2022, 21(1): 97.

[31] [31] HAN D, LIU J, CHEN C, et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells[J]. Nature, 2019, 566(7743): 270-274.

[33] [33] FANG H, SUN Q, ZHOU J, et al. m6A methylation reader IGF2BP2 activates endothelial cells to promote angiogenesis and metastasis of lung adenocarcinoma[J]. Mol Cancer, 2023, 22(1): 99.

[34] [34] HONG Y, QIN H, LI Y, et al. FNDC3B circular RNA promotes the migration and invasion of gastric cancer cellsviathe regulation of E-cadherin and CD44 expression[J]. J Cell Physiol, 2019, 234(11): 19895-19910.

[35] [35] LI E, XIA M, DU Y, et al. METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis[J]. eLife, 2022, 11: e75231.

[36] [36] WANG Y, WANG C, GUAN X, et al. PRMT3-mediated arginine methylation of METTL14 promotes malignant progression and treatment resistance in endometrial carcinoma[J]. Adv Sci (Weinh), 2023, 10(36): e2303812.

[37] [37] XU Y Y, LI T, SHEN A, et al. FTO up-regulation induced by MYC suppresses tumour progression in Epstein-Barr virus-associated gastric cancer[J]. Clin Transl Med, 2023, 13(12): e1505.

[38] [38] LIU L, GU M, MA J, et al. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma[J]. Mol Cancer, 2022, 21(1): 149.

[39] [39] LIU Z, CHEN J, REN Y, et al. Multi-stage mechanisms of tumor metastasis and therapeutic strategies[J]. Signal Transduct Target Ther, 2024, 9(1): 270.

[41] [41] HUANG Y, XIA W, DONG Z, et al. Chemical inhibitors targeting the oncogenic m6A modifying proteins[J]. Acc Chem Res, 2023, 56(21): 3010-3022.